Clinical Operations Fellowship at Roivant Sciences

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Internship, Entry Level & New GradExperience Level

InternshipJob Type

UnknownVisa

BiopharmaceuticalIndustries

Requirements

Eager to shape the future of drug development and launch career at intersection of science and strategy
Ready to lead, build, and make an impact from day one in a hands-on 2-year fellowship
Interest in clinical operations for driving operational excellence in timelines, budgets, and site engagement

Responsibilities

Own impact: Apply intellect to drive operational excellence in timelines, budgets, and site engagement
Build key relationships with KOLs, PIs, site research teams, and advocacy groups
Lead from day one: Collaborate with Clinical Development and Operations Teams, Site Leads, and external partners to deliver high-quality trials on time and on budget
Think globally: Learn ICH-GCP standards and navigate regulatory pathways
Develop as a leader: Access executive mentorship and build fast track towards R&D and broader operational leadership roles
Trial set-up and oversight: Initiation and execution of clinical trials, including CRO/vendor selection and setup, site strategy, contracts & budgets, CRO/vendor oversight, system integration (eTMF, EDC, CTMS, IRT, etc.)

Skills

Clinical Operations

Clinical Trials

Study Execution

Regulatory Frameworks

Cross-functional Collaboration

Global Operations

Drug Development

Roivant Sciences

Develops biopharmaceuticals and RNA therapeutics

About Roivant Sciences

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house development with strategic partnerships, allowing it to build a strong pipeline of drug candidates and utilize advanced technologies to meet medical needs. A key subsidiary, Genevant, specializes in RNA therapeutics, employing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

New York City, New YorkHeadquarters

2014Year Founded

$1,750.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Risks

Integration challenges from Dermavant acquisition may disrupt operations and delay development.

Regulatory hurdles in Pulmovant collaboration with Bayer could impede progress.

Failure of lupus drug brepocitinib may lead to financial losses and investor concerns.

Differentiation

Roivant Sciences focuses on late-stage drug candidates, reducing development time and cost.

The company builds Vants, nimble biotech firms, to enhance drug development efficiency.

Roivant leverages RNA therapeutics, including mRNA and RNAi, for innovative treatments.

Upsides

Roivant's acquisition of Dermavant expands its dermatology portfolio and therapeutic areas.

Strategic partnerships with Bayer and Roche accelerate drug development and market entry.

Increased investment from financial institutions highlights confidence in Roivant's growth potential.

Land your dream remote job 3x faster with AI

Try Jobo Free